Trial site
Praxis Pesquisa Médica
Santo André, São Paulo 09090-790, BrazilNot linked to an institution yet
- 15running trials
- 4closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 2/32 trials
- Phase 21 trial
- Phase 41 trial
- Status
- Active, not recruiting11 trials
- Recruiting3 trials
- Completed2 trials
- Terminated2 trials
- Enrolling by invitation1 trial
- Lead sponsor
- Eli Lilly and Company4 trials
- Agios Pharmaceuticals, Inc.3 trials
- Amgen3 trials
- Boehringer Ingelheim2 trials
- Hoffmann-La Roche2 trials
- and 5 more
Running trials
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603· Phase 3· Eli Lilly and Company· Source
Enrolling by invitation
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
NCT05777993· Phase 4· Agios Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780· Phase 2/3· Agios Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
NCT04770753· Phase 3· Agios Pharmaceuticals, Inc.· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586023· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Atrasentan in Patients With IgA Nephropathy
NCT04573478· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error